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Background: FoxP3+ follicular regulatory T cells (Tfr) have been identified as the cell
population controlling T follicular helper (Tfh) cells and B cells which, are both involved in
effector immune responses against transplanted tissue.
Methods: To understand the biology of Tfr cells in kidney transplant patients treated
with tacrolimus and mycophenolate mofetil (MMF) combination immunosuppression, we
measured circulating (c)Tfh and cTfr cells in peripheral blood by flow cytometry in n= 211
kidney transplant recipients. At the time of measurement patients were 5–7 years after
transplantation. Of this cohort of patients, 23.2% (49/211) had been previously treated
for rejection. Median time after anti-rejection therapy was 4.9 years (range 0.4–7 years).
Age and gender matched healthy individuals served as controls.
Results: While the absolute numbers of cTfh cells were comparable between kidney
transplant recipients and healthy controls, the numbers of cTfr cells were 46% lower in
immunosuppressed recipients (p < 0.001). More importantly, in transplanted patients,
the ratio of cTfr to cTfh was decreased (median; 0.10 vs. 0.06), indicating a disruption
of the balance between cTfr and cTfh cells. This shifted balance was observed for
both non-rejectors and rejectors. Previous pulse methylprednisolone or combined
pulse methylprednisolone + intravenous immunoglobulin anti-rejection therapy led to a
non-significant 30.6% (median) and 51.2% (median) drop in cTfr cells, respectively when
compared to cTfr cell numbers in transplant patients who did not receive anti-rejection
therapy. A history of alemtuzumab therapy did lead to a significant decrease in cTfr cells
of 85.8% (median) compared with patients not treated with anti-rejection therapy (p <
0.0001). No association with tacrolimus or MMF pre-dose concentrations was found.
Niu et al. Immunosuppression Associated With Decreased cTfr
Conclusion: This cross-sectional study reveals that anti-rejection therapy with
alemtuzumab significantly lowers the number of cTfr cells in kidney transplant recipients.
The observed profound effects by these agents might dysregulate cTfr functions.
Keywords: kidney transplantation, antibody mediated rejection, anti-rejection therapy, donor specific antibodies,
flow cytometry, circulating Tfr, circulating Tfh, transplantation immunology
INTRODUCTION
Improvement of long-term outcomes after kidney
transplantation remains a challenge (1–5). The most recent
findings based on the United States registry data and
Collaborative Transplant Study across 21 European countries,
report only a slight improvement in renal allograft survival since
the early 2000’s (6–8). Antibody-mediated immune responses
are recognized as an important factor in late kidney allograft
failure (9–11). This immune response is refractory to treatment
with conventional immunosuppression (12–14).
Follicular T helper (Tfh) cells play a critical role in B cell-
dependent antibody generation (15–17). These Tfh cells co-
localize with B cells in germinal centers within secondary
lymphoid organs (SLOs) and are specialized in assisting antigen
activated B cells to differentiate into antibody-producing plasma
cells (18, 19). This immune response is controlled by follicular
regulatory T (Tfr) cells, a unique subset of regulatory T (Treg)
cells, that inhibits Tfh and B cell responses (20, 21). Tfr cells exert
immune inhibitory functions through down-regulating the co-
stimulatory molecule CD86 on B cells (22), producing inhibitory
cytokines e.g., interleukin (IL)-10 and mediating cytolysis (23).
Both Tfr and Tfh cells express high levels of CXC chemokine
receptor 5 (CXCR5) and programmed death 1 (PD-1) (24),
as well as the transcriptional factor B cell lymphoma (Bcl)-
6 (25, 26). Tfr cells can also express Helios a transcription
factor expressed by natural Tregs, and a marker reflecting
enhanced immunosuppressive functions (27). From studies in
patients suffering from auto-immune disease we know that the
dynamic balance between Tfr and Tfh cells is important for
immune homeostasis and tolerance. An aberrant Tfr/Tfh ratio
has been linked to the development of autoantibody immunity-
mediated diseases including systemic lupus erythematosus (28),
rheumatoid arthritis (29), and myasthenia gravis (30). Also
in kidney transplant recipients it was shown that antibody
mediated rejection (ABMR) and chronic allograft dysfunction are
associated with a disturbed balance of circulating (c)Tfh and cTfr
cells (31, 32).
The role of Tfh cells in alloreactivity was shown by de Graav
et al. (33) and de Leur et al. (34) who found that Tfh cells
are present in biopsies diagnosed as T cell-mediated rejection
(TCMR) and ABMR and that these Tfh cells provide help to
Abbreviations: Alem, alemtuzumab; ART, anti-rejection therapy; BPR, biopsy-
proven rejection; CNIs, calcineurin inhibitors; cTfh cell, circulating follicular
helper T cell; cTfr cell, circulating follicular regulatory T cell; DSA, donor-specific
antibodies; IVIg, intravenous immunoglobulin; KTx, kidney transplantation;
MMF, mycophenolate mofetil; MP, methylprednisolone; PBMC, peripheral blood
mononuclear cells; Pred, prednisolone; Tac, tacrolimus; TCMR, T cell-mediated
rejection.
alloantigen-activated B cells (35). From experimental transplant
models we know that Tfh cells are capable of stimulating
alloantibody production which in turn mediates the humoral
response against the allograft (36, 37). These findings highlight
the importance of Tfh cells in the process of transplant rejection
while the first data about Tfr cells point to their impaired function
in controlling the actions of Tfh cells in the allogeneic responses
after organ transplantation (32).
Immunosuppressive drugs, including the calcineurin
inhibitor (CNI) tacrolimus, may decrease the number and
impair the function of Tfh and Tfr cells (38). However, to what
extent immunosuppressive therapies affect the biology of Tfr and
Tfh cells after kidney transplantation is unknown.
In the present observational study, the absolute numbers of
Tfr cells and their relation to Tfh cells in immunosuppressed
renal transplant recipients and healthy controls was investigated.
In addition, the impact of anti-rejection therapy on these cell
populations was studied.
MATERIALS AND METHODS
Study Population
A cohort of 211 renal transplant recipients transplanted
between 2012 and 2014 was sampled cross sectionally at
the timepoint of 5.0–7.7 years (median 5.3) post-transplant.
All patients had a functional graft at the time of blood
sampling, kidney function was assessed by estimated glomerular
filtration rate (eGFR, mL/min per 1.73 m2) as calculated by the
CKD-EPI equation. Transplant recipients (n = 202) received
induction therapy with basiliximab [Simulect R©; Novartis, Basel,
Switzerland; 20mg intravenously on days 0 and 4], rabbit
anti-thymocyte globulin [Thymoglobulin R©, Sanofi Genzyme,
United States (n = 2) or rituximab [MabThera R©; Roche,
Basel, Switzerland (n = 7) for blood group ABO incompatible
kidney transplantation [rituximab 375 mg/m2 4 weeks before
transplantation; tacrolimus 0.1 mg/kg b.i.d, mycophenolate
mofetil (MMF) 1,000mg b.i.d; prednisone 20mg once daily
starting 2 weeks before transplantation]. The post-operative
immunosuppressive regimen after transplantation consisted of
tacrolimus (Prograf R©; Astellas Pharma, Tokyo, Japan; aiming
for pre-dose concentrations of 10–15 ng/mL in weeks 1–2,
8–12 ng/mL in weeks 3–4 and 5–10 ng/mL thereafter), MMF
(Cellcept R©; Roche, Basel, Switzerland; starting dose of 1 g twice
a day, aiming for pre-dose concentrations of 1.5–3.0 mg/L) and
prednisolone. Prednisolone was tapered to 5mg at month 3
and withdrawn at months 4–5. In patients who experienced a
rejection event, prednisolone was reintroduced to 10mg once
daily. Rejection was defined as presumed, treated acute rejection
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(in patients who had no biopsy or an inconclusive biopsy) or
biopsy-proven rejection (BPR) as part of routine clinical care by
a renal pathologist using 2µm paraffin sections stained for HE,
PAS, Jones and immunohistochemistry for C4d on 4µmsections.
After the completion of the study, all biopsies were reviewed
again by a clinical pathologist (M.C.C.) in a blinded fashion per
the Banff’15 classification (39). Patients suffering from vascular
(Banff grade 2) or tubulo-interstitial (Banff grade 1) rejection
received high-dose pulse intravenous methylprednisolon as first-
line therapy (methylprednisolone 1,000mg i.v. for 3 consecutive
days), whereas patients suffering from severe or glucocorticoid-
resistant acute rejection were treated with alemtuzumab (one
or two doses of 30mg s.c.). Patients suffering from ABMR or
mixed-type rejection (TCMR and ABMR) were treated with
methylprednisolone plus intravenous immunoglobulins (IVIg)
(40, 41). While the majority of patients in our study were treated
according to the above mentioned guidelines, there are some
instances where biopsy scores were changed after the second
biopsy revision done according to the Banff’15 classification. A
disparate treatment from the guidelines was also chosen for a
few patients for other clinical reasons (e.g., suspicion of humoral
immunity components or patient history).
Thirty age and gender-matched healthy controls were also
included. All patients (MEC-2016-718, NL59284.078.16) and
healthy controls (MEC-2018-1623.; NL66443.078.18) provided
written informed consent. The baseline demographic and clinical
characteristics of patients and controls are summarized in
Table 1.
Flow Cytometry
Fresh peripheral blood samples (5–7 years post-transplant) were
collected in 6ml heparin tubes (BD Biosciences, San Jose, CA)
and stored at room temperature on a tube-roller. Blood samples
were processed within 2 h after drawing blood. Peripheral blood
mononuclear cells (PBMCs) were isolated using Ficoll gradient
medium (Histopaque-1077, Sigma-Aldrich, St. Louis, MI). In
brief, the surface and intracellular staining of PBMCs were
performed using the following monoclonal antibodies (mAbs):
anti-CD3 BV510 (OKT3, Biolegend, San Diego, CA); anti-CD4
BV421 (RPA-4, Biolegend); anti-CXCR5 AF647 (RF8B2, BD
Biosciences); anti-Foxp3 PE (PCH101, Invitrogen, Amsterdam,
the Netherlands); anti-PD-1 APC-Cy7 (EH12.2H7, Biolegend);
Helios PerCP-Cy5.5 (22F6, Biolegend). The following CD4+
T cell subpopulations were studied and defined as: total cTfh
(CD3+CD4+CXCR5+Foxp3−), total cTfr (CD3+CD4+CXCR
5+Foxp3+), PD-1+cTfh (CD3+CD4+CXCR5+Foxp3−PD-1+),
PD-1+cTfr (CD3+CD4+CXCR5+Foxp3+PD-1+), and Helios
+cTfr (CD3+CD4+CXCR5+Foxp3+Helios+). To calculate
absolute numbers of CD19+, CD4+ cells and the above described
subsets, BD multi-test 6-color R© was used in combination with
BD TruCount Tubes R© (BD Biosciences). Absolute numbers
of CD4T cell subsets were calculated using the percentages
of these subsets within the total CD4 population. Cells were
acquired using a BD Canto II flow cytometer and results were
analyzed with Kaluza V2.1 software. Gating strategies are shown
in Figure 2.
TABLE 1 | Characteristics of kidney transplantation recipients and healthy
controls.
KTx patients HCs
Recipient
Number 211 30
Agea, years, median (range) 55 (21-77) 55 (25-78)
Male gender, n (%) 143 (67.8) 21 (70.0)
Primary disease, N (%)
Hypertensive nephropathy 41 (19.4)
Polycystic kidney disease 33 (15.6)
Diabetes mellitus 32 (15.2)
Glomerulonephritis/pyelonephritis 17 (8.1)
IgA nephropathy 15 (7.1)
Focal segmental glomerulosclerosis 9 (4.3)
Other 38 (18.0)
Unknown 26 (12.3)
Donor
Donor age, years, median (range) 54 (0–82)
Living donor, n (%) 155 (73.5)
HLA mismatch, n (%)
0–2 60 (28.4)
3–4 92 (43.6)
5–6 59 (28.0)
Induction therapy
Anti-CD25 mAb 202 (95.7)
Rituximab 7 (3.3)
Anti-thymocyte globulin 2 (1.0)
Immunosuppression, n (%)
Tac/MMF 181 (85.8)
Tac monotherapy 30 (14.2)
Previous KTx, n (%)
Second/third/fourth KTx 19 (9.0)/5 (2.2)/3 (1.3)
PRA, mean (range)
Current 5.0 (0–83)
Highest 12.8 (0–100)
Time after KTx, years, median (range) 5.3 (5.0–7.7)
Occurrence of rejection, n (%)
No 162 (76.8)
Yes 49 (23.2)
First episode within 1Y after KTx 38 (18.0)
Rejection type, n (%)
TCMR/ABMR/mixed TCMR and ABMR* 29 (13.7)/15 (7.1)/5 (1.4)
aAge at transplantation for patients. KTx, kidney transplantation; HCs, healthy controls;
Pred, prednisolone; Tac, tacrolimus; MMF, mycophenolate mofetil; Anti-CD25 mAb,
anti-CD25 monoclonal antibody; Ab, antibody; 1Y, 1 year; TCMR, T cell-mediated
rejection; cABMR, chronic antibody-mediated rejection *According to the Banff 2015
classification (39).
Detection of Anti-HLA Antibodies
The complement-dependent cytotoxicity cross-match was
negative before transplantation in all patients. Serum samples
from recipients were screened for the presence of HLA antibodies
using the Lifecodes Lifescreen Deluxe (LMX) kit, according to
the manufacturer’s manual (Immucor Transplant Diagnostics
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Inc. Stamford, CT, USA) 5–7 years post-transplant at the time of
blood sampling. Anti-HLA class I (HLA-A, HLA-B, or HLA-C)
or HLA class II (HLA-DR or HLA-DQ) antibodies were further
analyzed with a Luminex Single Antigen assay using LABscreen
HLA class I and class II antigen beads (One Lambda, Canoga
Park, GA, USA), as described in our previous study (42). The
presence of donor-specific antibodies (DSA) was determined
by comparing the various HLA specificities with donor
HLA typing.
Statistical Analyses
Data are presented as median with interquartile range (IQR),
unless otherwise specified. The Mann–Whitney U-test was
used for comparisons between two groups. The Kruskal-
Wallis test with Dunn’s test for multiple comparisons was
used for comparisons between three or more groups. The
association between two variables was analyzed by Spearman’s
correlation and graphically represented by scatter plot. Statistical
analysis was performed by IBM SPSS version 25 (Armonk, NY,
USA). P-values with a two-sided α < 0.05 were considered
statistically significant.
RESULTS
Characteristics of the Kidney Transplant
Recipients
Table 1 depicts the characteristics of the study cohort and
healthy controls (HCs). The majority of patients were male
(67.8%) and received their first kidney transplant (87.5%)
from a living donor (73.5%). Out of 211 patients, 49
patients (n = 5 presumed, treated rejection, and n = 44
BPR) (23.2%) experienced a rejection of whom 32 recipients
(15.2%) experienced one rejection episode, 14 patients (6.6%)
had two rejection episodes and 3 patients (1.4%) had three
rejection episodes. The majority of patients, 38 out of
49 (77.6%), developed a rejection within the first year
after transplantation.
FIGURE 1 | Overview of the kidney transplant recipients with a biopsy-proven rejection before blood sampling and the type of anti-rejection therapy administered.
BPR, biopsy-proven rejection; ART, anti-rejection therapy; MP, methylprednisolone; IVIg, intravenous immunoglobulin; Alem, alemtuzumab.
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FIGURE 2 | Gating strategy for analysis of circulating follicular T cells. Measurements were performed on freshly drawn blood samples. Lymphocytes (A) were gated
based on forward and side scatter. CD3+ cells (B) were used to identify T cells and CD4+ cells (C) were used for further analysis. Foxp3 and CXCR5 were used to
distinguish conventional T cells, regulatory T cells, circulating follicular regulatory T cells, and circulatory follicular helper T cells (D). The expression markers PD-1 and
Helios were used to further identify the subsets of circulating follicular regulatory T cells (E) and circulating follicular helper T cells (F). Isotype controls were done to
ensure proper gating (G).
An overview describing the number of patients who
developed a rejection and received anti-rejection therapy is given
in Figure 1.
The Effect of Tacrolimus-Based
Immunosuppression on cTfr and cTfh Cell
Numbers in Kidney Transplant Recipients
We studied the differences in absolute cell numbers of Tfr
and Tfh cells and their PD-1 and Helios expression between
kidney transplant recipients and HCs. The gating strategy is
shown in Figure 2. The numbers of both total cTfr (CD3+CD
4+CXCR5+FoxP3+), PD-1+cTfr (CD3+CD4+CXCR5+FoxP
3+PD-1+), and Helios+cTfr (CD3+CD4+CXCR5+FoxP3+
Helios+) cells were significantly lower in patients when
compared to healthy controls (Figure 3A), while the numbers of
both total cTfh (CD3+CD4+CXCR5+FoxP3−) and PD-1+cTfh
(CD3+CD4+CXCR5+FoxP3−PD-1+) in patients and controls
were not significantly different (Figure 3B). The decreased
cTfr numbers resulted in significantly lower cTfr/cTfh, PD-
1+cTfr/PD-1+cTfh and Helios+cTfr/ PD-1+cTfh ratios in
patients (Figure 3C). Finally, we examined whether the cTfh and
cTfr populations were associated with kidney graft function. We
found that the number of total cTfr cells, and ratio of cTfr to
cTfh were both positively correlated with eGFR (Figure S1). All
other cell types showed no significant correlation with kidney
graft function.
Numbers of cTfr and cTfh in Patients With
Anti-HLA Antibodies and Donor-Specific
Antibodies
In this study, anti-HLA antibodies were measured for all patients
at the time of blood sampling. Out of 211 patients, 34 (16.1%)
patients had detectable anti-HLA antibodies, of which 11 (5.2%)
were DSA positive. The association between the numbers of
cTfr and cTfh cells with the presence of anti-HLA antibodies
or DSA was analyzed. No significant differences were observed
between absolute numbers of cTfr, cTfh, and cell ratios (Figure 4)
in patients with anti-HLA antibodies or DSA at the time of
blood sampling.
cTfr and cTfh in Patients With a History of
Rejection and the Effect of Anti-rejection
Therapy on Their Cell Numbers
To define whether alloreactivity and subsequent anti-rejection
therapy affect cTfr and cTfh cell numbers, we first grouped the
samples according to the rejection history and later according to
the type of anti-rejection therapy (Figure 1). The 211 patients
were divided into a group with a history of rejection (n = 5
presumed, treated rejection, and n = 44 BPR) and a group with
no previous rejection (n = 162). Compared to patients without
rejection, patients with a history of rejection had 43.9, 39.4, and
39% lower numbers of cTfr, PD-1+cTfr, and Helios+cTfr cells,
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FIGURE 3 | Changes in cTfr and cTfh cell numbers in all kidney transplant patients. The above image shows the absolute numbers (cells/µL) of cTfr cells and its
subsets (A), absolute numbers (cells/µL) of cTfh and its subset (B), and cell ratios of cTfr to cTfh and ratios of their subsets (C). Boxplots represent the median and
interquartile ranges and the whiskers show the 95% confidence interval. KTx, kidney transplantation; HCs, healthy controls. Mann-Whitney-U-test, **p < 0.01; ***p <
0.001; and ****p < 0.0001.
respectively. Furthermore, in the rejection patients cTfh and PD-
1+cTfh cell numbers were 42.8 and 39.2% lower, respectively.
Due to the significant decrease of both cTfr and cTfh, all cell ratios
in patients with or without a history of rejection were comparable
(Figure 5A). Additionally, we examined whether there were
any significant differences in absolute cell numbers between
patients with different types of BPR. Patients with rejection were
categorized into three subgroups according to their latest biopsy
results: TCMR (n = 29), ABMR (n = 15), mixed TCMR and
ABMR (n = 5). We found no significant differences in cTfr and
cTfh absolute cell numbers between patients with different types
of rejection (Figure S2).
Patients with a history of rejection received anti-
rejection therapy at a median time of 4.9 years before blood
sampling. Since there could be a difference in the effects
of the various anti-rejection treatments on follicular cell
numbers, patients were grouped accordingly. Patients were
treated with high-dose pulse intravenous methylprednisolon
only, high-dose pulse intravenous methylprednisolon with
intravenous immunoglobulin or high-dose pulse intravenous
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FIGURE 4 | Cell ratios of absolute numbers of cTfr to cTfh in patients with or
without anti-HLA antibodies or donor-specific antibodies. The above image
shows the ratios of cTfr to cTfh. Boxplots represent the median and
interquartile ranges and the whiskers show the 95% confidence interval. aHLA,
anti-HLA antibodies; DSA, donor-specific antibodies.
methylprednisolon with alemtuzumab at a median time of 5.1
(range: 2.1–7.1), 2.5 (0.4–6.5), and 5.0 (2.5–6.1) years before
blood sampling, respectively. Table 2 provides an overview of
the cohort of 49 patients who received anti-rejection therapy
before blood sampling. As expected, alemtuzumab treatment
had the strongest effect, and it was the only anti-rejection
treatment associated with significantly lower numbers of both
cTfr and cTfh cells, including their subsets. When compared
to patients who had not been treated with anti-rejection
therapy, the median absolute numbers of total cTfr in patients
treated with previous pulse methylprednisolone decreased
by 30.6%, pulse methylprednisolone + IVIg led to 51.2%
decrease and pulse methylprednisolone + alemtuzumab led
to 85.8% decrease. Absolute numbers of total cTfr, PD-1-
cTfr, and Helios+cTfr in patients who had received pulse
methylprednisolone + alemtuzumab were significantly lower
than cell numbers of patients who had received no anti-rejection
treatment (Figure 5B). Treatment with other anti-rejection
therapies did not result in a significant measurable decrease of
total cTfr or activated cTfr absolute numbers compared to no
anti-rejection treatment.
Similarly, absolute numbers of total cTfh in patients
treated with previous pulse methylprednisolone decreased by
42.7%, pulse methylprednisolone + IVIg resulted in 32.6%
decrease and pulse methylprednisolone+ alemtuzumab resulted
in 66.8% decrease compared to total cTfh numbers in
patients who had not been treated with anti-rejection therapy.
This decrease in absolute numbers of total cTfh was only
significant for patients treated with pulse methylprednisolone
+ alemtuzumab, while PD-1+cTfh were not significantly
lower compared to patients who did not receive anti-
rejection therapy (Figure 5C). The ratio of total cTfr to
cTfh and Helios+cTfr to PD-1+Tfh were also significantly
lower in patients who received pulse methylprednisolone +
alemtuzumab anti-rejection therapy (Figure 5D). We found
a similar decrease in CD3+, CD4+, and T conventional
cells in patients treated with pulse methylprednisolone +
alemtuzumab anti-rejection therapy. Interestingly, Treg cell
numbers were not significantly lower in patients who received
pulse methylprednisolone+ alemtuzumab anti-rejection therapy
(Figure S3).
DISCUSSION
In the present study, we investigated whether
immunosuppression affects the absolute numbers of cTfr
and cTfh cells and the balance between cTfr to cTfh cells
in kidney transplant recipients. We found that tacrolimus-
based maintenance immunosuppression results in decreased
absolute numbers of cTfr cells, without affecting cTfh cells
when compared to healthy individuals. Other studies in renal
transplant recipients, demonstrated increased cTfh cell numbers
before the development of DSA, in association with ABMR
or with the development of anti-HLA antibodies (43–45).
Moreover, decreased numbers of Tfr cells were observed
in both kidney transplant tissue and peripheral blood of
patients with ABMR (32). The majority of patients in our
cohort were on a combined maintenance treatment with
tacrolimus and MMF. MMF is a known inhibitor of lymphocyte
proliferation (46) and calcineurin inhibitors have an adverse
effect on the differentiation and function of regulatory T
cells (47–49). Circulating Tfr cells are primarily derived from
Tregs (50) so it stands to reason that if Treg differentiation
is inhibited then this may also have a direct effect on cTfr
cell numbers.
We also found that patients with anti-HLA antibodies
or DSA at 5–7 years post-transplant had similar cTfr and
cTfh cell numbers as patients without antibodies. This is
somewhat unexpected as other studies have shown elevated
numbers of cTfh in patients with anti-HLA antibodies or
DSA (45, 51). In this study, 13 of the 34 patients with anti-
HLA antibodies had a history of rejection and anti-rejection
therapy. This suggests that the immunosuppression regimen
and/or anti-rejection therapy administered to our patients
is able to prevent the expansion of cTfh cells which are
commonly associated with the presence of anti-HLA antibodies.
However, it may not be sufficient to completely suppress
previously formed Tfh and memory B cells from developing
anti-HLA antibodies.
As demonstrated in this study, treatment with alemtuzumab
led to significantly lower numbers of total and subsets of cTfr
and total cTfh cells. After administration of alemtuzumab, T
cells repopulation occurs through the clonal expansion of T cells
as opposed to repopulation though thymopoiesis, in a process
known as homeostatic proliferation (52–54). Our findings
suggest that the homeostatic proliferation of cTfr cells is impaired
after treatment with alemtuzumab. This is in line with the
findings of Macedo et al., who showed that Tregs are significantly
decreased compared to HCs several years after alemtuzumab
induction (55). Moreover, the resulting shift in balance between
Tfr to Tfh cells after treatment with alemtuzumab may result
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FIGURE 5 | Absolute numbers and ratios of cTfr, cTfh, and their subsets in healthy controls and patients who received different types of anti-rejection therapy. The
above image shows the ratio of cTfr to cTfh in patients with and without rejection (A). Also shown are the absolute numbers (cells/µL) of cTfr cells and its subsets (B),
absolute numbers (cells/µL) of cTfh and its subset (C), and cell ratios of cTfr to cTfh and ratios of their subsets (D). Boxplots represent the median and interquartile
ranges and the whiskers show the 95% confidence interval. HC, healthy controls; ART, anti-rejection therapy; MP, methylprednisolone; IVIg, intravenous
immunoglobulin; Alem, alemtuzumab. Kruskal–Wallis with Dunn’s multiple comparisons. **p < 0.01; ***p < 0.001; and ****p < 0.0001.
in increased formation of memory B cells and plasma blasts
thereby increasing the risk for development of ABMR. Clinical
studies have reported that alemtuzumab induction therapy, is
associated with a higher incidence of chronic ABMR in kidney
transplant recipients (56, 57). It is unclear whether alemtuzumab
therapy has an effect on follicular T cells and B cells which reside
in SLOs. If these cells remain present in SLOs, T and B cell
cross-talk can still result in the formation of memory B cells
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TABLE 2 | Characteristics of the 49 kidney transplant recipients who received
anti-rejection therapy.
Anti-rejection therapy
MP only
(n = 24)
MP + IVIg
(n = 17)
MP + alemtuzumab
(n = 8)
Patients with rejection (n = 49)
Rejection episodes, n (%)
One episode (n = 32) 20 (40.8) 8 (8.9) 4 (8.1)
Two episodes (n = 14) 4 (8.1) 6 (12.2) 4 (8.1)
Three episodes (n = 3) 0 3 (6.1) 0
Rejection type, n (%)
TCMR (n = 29) 20 (40.8) 4 (8.1) 5 (10.2)
ABMR (n = 15) 3 (6.1) 10 (20.4) 2 (4.1)
Mixed TCMR and ABMR (n = 5) 1 (2.0) 3 (6.1) 1 (2.0)
KTx, kidney transplantation; ART, anti-rejection therapy; MP, methylprednisolone;
IVIg, intravenous immunoglobulin; TCMR, T cell-mediated rejection; ABMR, antibody-
mediated rejection.
and antibody-producing B cells. It is also interesting to note
that despite successful treatment of rejection, the patients in our
cohort have a higher incidence of anti-HLA antibodies and DSA
up to 5 years after treatment with anti-rejection therapy.
Nonetheless, the results presented in this study should
be interpreted in light of the study limitations. The patient
cohort described here is heterogeneous and includes patients
treated with different modalities of anti-rejection therapy and
differences in the timing of treatment. While this heterogeneity
is representative of daily clinical practice, it provides a challenge
when interpreting our results. Another limitation is the fact that
cell counts prior to treatment with anti-rejection therapy are
not available. Ideally, serial measurements both before and after
treatment with said therapies would provide interesting data.
As comparisons with pre-treatment samples are not possible
to conclude with certainty whether cTfh cell numbers are less
affected by anti-rejection therapy or whether there is a faster
repopulation of this subset compared to that of cTfr cells.
And finally, the challenges in acquiring sufficient numbers of
follicular T cells in transplant recipients results in a lack of
assays to describe the functionality of these cells after treatment
with maintenance and anti-rejection therapy. The use of a
mouse animal model might be valuable method to study the
mechanisms of follicular T cells in vivo. Moreover, by using a
mouse monoclonal antibody against the CD52 molecule it would
also be possible to study the effect of alemtuzumab on follicular
T cells and B cells present both in the circulation and in SLOs.
In conclusion, compared to healthy controls, numbers of
cTfr cells in peripheral blood of kidney transplant recipients
on tacrolimus-based therapy are significantly lower up to 7
years after transplantation. Furthermore, previous treatment
with alemtuzumab has a significant and long-lasting effect on the
numbers of these cells.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by METC Erasmus Medisch Centrum Rotterdam. The
patients/participants provided their written informed consent to
participate in this study.
AUTHOR CONTRIBUTIONS
QN, AM, CB, NB, TG, and DH: conceptualization. MD
and CB: methodology. MD, QN, and AM: investigation.
QN and AM: formal analysis. QN, AM, and CB: writing-
original draft. LW, NB, TG, and DH: editing. NB and
CB: supervision. MD and NB: project administration.
All authors contributed to the article and approved the
submitted version.
FUNDING
This work was supported by the Erasmus MC (mRACE grant
2016) and the National Natural Science Foundation of China
(Grant Nos. 81501816, 81871713, and 81571561).
ACKNOWLEDGMENTS
We are grateful for the contributions of our lab members.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2020.01972/full#supplementary-material
Figure S1 | Correlations of cTfr absolute cell numbers (A), cTfh absolute cell
numbers (B), and ratio of cTfr to Tfh (C) with kidney function. Spearman’s
correlation.
Figure S2 | Absolute numbers and cell ratios of cTfr, cTfh, and their activated
subset by type of rejection. Shown are the absolute numbers (cells/µL) of cTfr
cells and its subsets (A), absolute numbers (cells/µL) of cTfh and its subset (B),
and cell ratios of cTfr to cTfh and ratios of their subsets (C). Boxplots represent
the median and interquartile ranges and the whiskers show the 95% confidence
interval. TCMR, T cell-mediated rejection; ABMR, antibody-mediated rejection;
Mixed, mixed TCMR and ABMR. Kruskal–Wallis test.
Figure S3 | Absolute numbers of CD3, CD4, T conventional cells and Treg cells in
healthy controls and patients who received different types of anti-rejection therapy.
The above image shows the absolute numbers (cells/µL) of CD3 cells (A), CD4
cells (B), T conventional cells (C), and Treg cells (D). Boxplots represent the
median and interquartile ranges and the whiskers show the 95% confidence
interval. HC, healthy controls; ART, anti-rejection therapy; MP, methylprednisolone;
IVIg, intravenous immunoglobulin; Alem, alemtuzumab. Kruskal–Wallis with Dunn’s
multiple comparisons. ∗p < 0.05 and ∗∗p < 0.01.
Frontiers in Immunology | www.frontiersin.org 9 August 2020 | Volume 11 | Article 1972
Niu et al. Immunosuppression Associated With Decreased cTfr
REFERENCES
1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of
improvement in renal allograft survival despite a marked decrease in
acute rejection rates over the most recent era. Am J Transplant. (2004)
4:378–83. doi: 10.1111/j.1600-6143.2004.00332.x
2. Gaston RS, Fieberg A, Hunsicker L, Kasiske BL, Leduc R, Cosio FG, et al.
Late graft failure after kidney transplantation as the consequence of late versus
early events. Am J Transplant. (2018) 18:1158–67. doi: 10.1111/ajt.14590
3. Stegall MD, Gaston RS, Cosio FG, Matas A. Through a glass darkly: seeking
clarity in preventing late kidney transplant failure. J Am Soc Nephrol. (2015)
26:20–9. doi: 10.1681/ASN.2014040378
4. Wekerle T, Segev D, Lechler R, Oberbauer R. Strategies for long-
term preservation of kidney graft function. Lancet. (2017) 389:2152–
62. doi: 10.1016/S0140-6736(17)31283-7
5. Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De
Geest S, et al. Practical recommendations for long-term management of
modifiable risks in kidney and liver transplant recipients: a guidance report
and clinical checklist by the Consensus on Managing Modifiable Risk in
Transplantation (COMMIT) group. Transplantation. (2017) 101(4S Suppl.
2):S1–56. doi: 10.1097/TP.0000000000001651
6. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival
in the United States: a critical reappraisal. Am J Transplant. (2011) 11:450–
62. doi: 10.1111/j.1600-6143.2010.03283.x
7. Keith DS, Vranic G, Nishio-Lucar A. Graft function and intermediate-
term outcomes of kidney transplants improved in the last decade: analysis
of the United States kidney transplant database. Transplant Direct. (2017)
3:e166. doi: 10.1097/TXD.0000000000000654
8. Coemans M, Susal C, Dohler B, Anglicheau D, Giral M, Bestard O,
et al. Analyses of the short- and long-term graft survival after kidney
transplantation in Europe between 1986 and 2015. Kidney Int. (2018) 94:964–
73. doi: 10.1016/j.kint.2018.05.018
9. Cippà PE, Liu J, Sun B, Kumar S, Naesens M, McMahon
AP. A late B lymphocyte action in dysfunctional tissue repair
following kidney injury and transplantation. Nat Commun. (2019)
10:1157. doi: 10.1038/s41467-019-09092-2
10. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio
FC, et al. Evidence for antibody-mediated injury as a major
determinant of late kidney allograft failure. Transplantation. (2010)
90:68–74. doi: 10.1097/TP.0b013e3181e065de
11. Bouatou Y, Viglietti D, Pievani D, Louis K, Duong Van Huyen J-P, Rabant
M, et al. Response to treatment and long-term outcomes in kidney transplant
recipients with acute T cell–mediated rejection.Am J Transpl. (2019) 19:1972–
88. doi: 10.1111/ajt.15299
12. Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann
M, et al. A randomized trial of bortezomib in late antibody-mediated
kidney transplant rejection. J Am Soc Nephrol JASN. (2018) 29:591–
605. doi: 10.1681/ASN.2017070818
13. Budde K, Dürr M. Any progress in the treatment of antibody-
mediated rejection? J Am Soc Nephrol JASN. (2018) 29:350–
2. doi: 10.1681/ASN.2017121296
14. Loupy A, Lefaucheur C. Antibody-mediated rejection of solid-organ
allografts. N Engl J Med. (2018) 379:1150–60. doi: 10.1056/NEJMra
1802677
15. McHeyzer-Williams LJ, Pelletier N, Mark L, Fazilleau N, McHeyzer-Williams
MG. Follicular helper T cells as cognate regulators of B cell immunity. Curr
Opin Immunol. (2009) 21:266–73. doi: 10.1016/j.coi.2009.05.010
16. Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G,
et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular
cells and contain specific subsets that differentially support antibody secretion.
Immunity. (2011) 34:108–21. doi: 10.1016/j.immuni.2010.12.012
17. Shulman Z, Gitlin AD, Weinstein JS, Lainez B, Esplugues E, Flavell RA, et al.
Dynamic signaling by T follicular helper cells during germinal center B cell
selection. Science. (2014) 345:1058–62. doi: 10.1126/science.1257861
18. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG.
Follicular helper T cells: lineage and location. Immunity. (2009) 30:324–
35. doi: 10.1016/j.immuni.2009.03.003
19. van Besouw NM, Mendoza Rojas A, Baan CC. The role of follicular T helper
cells in the humoral alloimmune response after clinical organ transplantation.
HLA. (2019) 94:407–14. doi: 10.1111/tan.13671
20. Wing JB, Tekguc M, Sakaguchi S. Control of germinal center
responses by T-follicular regulatory cells. Front Immunol. (2018)
9:1910. doi: 10.3389/fimmu.2018.01910
21. Sage PT, Sharpe AH. T follicular regulatory cells in the regulation of B cell
responses. Trends Immunol. (2015) 36:410–8. doi: 10.1016/j.it.2015.05.005
22. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM,
et al. CTLA-4 controls follicular helper T-cell differentiation by regulating
the strength of CD28 engagement. Proc Natl Acad Sci USA. (2015) 112:524–
9. doi: 10.1073/pnas.1414576112
23. Miles B, Connick E. Control of the germinal center by follicular
regulatory t cells during infection. Front Immunol. (2018)
9:2704. doi: 10.3389/fimmu.2018.02704
24. Sage PT, Francisco LM, Carman CV, Sharpe AH. The receptor PD-1 controls
follicular regulatory T cells in the lymph nodes and blood. Nat Immunol.
(2013) 14:152–61. doi: 10.1038/ni.2496
25. Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, et al. Follicular
regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center
reactions. Nat Med. (2011) 17:983–8. doi: 10.1038/nm.2426
26. Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and
regulation of T follicular helper cells. J Exp Med. (2012) 209:1241–
53. doi: 10.1084/jem.20120994
27. Linterman MA, Pierson W, Lee SK, Kallies A, Kawamoto S, Rayner TF, et al.
Foxp3+ follicular regulatory T cells control the germinal center response. Nat
Med. (2011) 17:975–82. doi: 10.1038/nm.2425
28. Xu B, Wang S, Zhou M, Huang Y, Fu R, Guo C, et al. The ratio of
circulating follicular T helper cell to follicular T regulatory cell is correlated
with disease activity in systemic lupus erythematosus. Clin immunol. (2017)
183:46–53. doi: 10.1016/j.clim.2017.07.004
29. Niu Q, Huang Z-C, Wu X-J, Jin Y-X, An Y-F, Li Y-M, et al. Enhanced IL-
6/phosphorylated STAT3 signaling is related to the imbalance of circulating
T follicular helper/T follicular regulatory cells in patients with rheumatoid
arthritis. Arthr Res Ther. (2018) 20:200. doi: 10.1186/s13075-018-1690-0
30. Zhao S, Ding J, Wang S, Li C, Guo P, Zhang M, et al. Decreased expression
of circulating Aire and increased Tfh/Tfr cells in myasthenia gravis patients.
Biosci Rep. (2018) 38:BSR20180096. doi: 10.1042/BSR20180096
31. Yan L, Li Y, Li Y, Wu X, Wang X, Wang L, et al. Increased circulating Tfh to
Tfr ratio in chronic renal allograft dysfunction: a pilot study. BMC Immunol.
(2019) 20:26. doi: 10.1186/s12865-019-0308-x
32. Chen W, Bai J, Huang H, Bi L, Kong X, Gao Y, et al. Low proportion of
follicular regulatory T cell in renal transplant patients with chronic antibody-
mediated rejection. Sci Rep. (2017) 7:1322. doi: 10.1038/s41598-017-01625-3
33. de Graav GN, Dieterich M, Hesselink DA, Boer K, Clahsen-van Groningen
MC, Kraaijeveld R, et al. Follicular T helper cells and humoral reactivity
in kidney transplant patients. Clin Exp Immunol. (2015) 180:329–
40. doi: 10.1111/cei.12576
34. de Leur K, Clahsen-van Groningen MC, van den Bosch TPP, de Graav
GN, Hesselink DA, Samsom JN, et al. Characterization of ectopic lymphoid
structures in different types of acute renal allograft rejection. Clin Exp
Immunol. (2018) 192:224–32. doi: 10.1111/cei.13099
35. de Leur K, Dor FJ, Dieterich M, van der Laan LJ, Hendriks RW,
Baan CC. IL-21 receptor antagonist inhibits differentiation of B cells
toward plasmablasts upon alloantigen stimulation. Front Immunol. (2017)
8:306. doi: 10.3389/fimmu.2017.00306
36. Conlon TM, Saeb-Parsy K, Cole JL, Motallebzadeh R, Qureshi MS, Rehakova
S, et al. Germinal center alloantibody responses are mediated exclusively by
indirect-pathway CD4T follicular helper cells. J Immunol. (2012) 188:2643–
52. doi: 10.4049/jimmunol.1102830
37. Alsughayyir J, Chhabra M, Qureshi MS, Mallik M, Ali JM, Gamper I, et al.
Relative frequencies of alloantigen-specific helper CD4T cells and B cells
determine mode of antibody-mediated allograft rejection. Front Immunol.
(2018) 9:3039. doi: 10.3389/fimmu.2018.03039
38. Wallin EF, Hill DL, Linterman MA, Wood KJ. The calcineurin inhibitor
tacrolimus specifically suppresses human t follicular helper cells. Front
Immunol. (2018) 9:1184. doi: 10.3389/fimmu.2018.01184
Frontiers in Immunology | www.frontiersin.org 10 August 2020 | Volume 11 | Article 1972
Niu et al. Immunosuppression Associated With Decreased cTfr
39. Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, et al. The Banff
2015 kidney meeting report: current challenges in rejection classification
and prospects for adopting molecular pathology. Am J Transplant. (2017)
17:28–41. doi: 10.1111/ajt.14107
40. van den Hoogen MWF, Hesselink DA, van Son WJ, Weimar
W, Hilbrands LB. Treatment of steroid-resistant acute renal
allograft rejection with alemtuzumab. Am J Transpl. (2013)
13:192–6. doi: 10.1111/j.1600-6143.2012.04328.x
41. Sablik KA, Clahsen-van Groningen MC, Looman CWN, Damman J, van
Agteren M, Betjes MGH. Treatment with intravenous immunoglobulins
and methylprednisolone may significantly decrease loss of renal function
in chronic-active antibody-mediated rejection. BMC Nephrology. (2019)
20:218. doi: 10.1186/s12882-019-1385-z
42. van Besouw NM, Yan L, de Kuiper R, Klepper M, Reijerkerk D, Dieterich
M, et al. The number of donor-specific IL-21 producing cells before and
after transplantation predicts kidney graft rejection. Front Immunol. (2019)
10:748. doi: 10.3389/fimmu.2019.00748
43. Chenouard A, Chesneau M, Bui Nguyen L, Le Bot S, Cadoux M, Dugast E,
et al. Renal operational tolerance is associated with a defect of blood Tfh
cells that exhibit impaired b cell help. Am J Transplant. (2017) 17:1490–
501. doi: 10.1111/ajt.14142
44. Shi J, Luo F, Shi Q, Xu X, He X, Xia Y. Increased circulating follicular helper T
cells with decreased programmed death-1 in chronic renal allograft rejection.
BMC Nephrol. (2015) 16:182. doi: 10.1186/s12882-015-0172-8
45. Cano-Romero FL, Laguna Goya R, Utrero-Rico A, Gomez-Massa E,
Arroyo-Sanchez D, Suarez-Fernandez P, et al. Longitudinal profile
of circulating T follicular helper lymphocytes parallels anti-HLA
sensitization in renal transplant recipients. Am J Transplant. (2019)
19:89–97. doi: 10.1111/ajt.14987
46. Allison AC, Eugui EM. Mycophenolate mofetil and its
mechanisms of action. Immunopharmacology. (2000) 47:85–
118. doi: 10.1016/S0162-3109(00)00188-0
47. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J,
et al. Inhibition of CD4+CD25+ regulatory T-cell function by
calcineurin-dependent interleukin-2 production. Blood. (2006)
108:390–9. doi: 10.1182/blood-2006-01-0329
48. Segundo DS, Ruiz JC, Izquierdo M, Fernandez-Fresnedo G, Gomez-
Alamillo C, Merino R, et al. Calcineurin inhibitors, but not
rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory
T cells in renal transplant recipients. Transplantation. (2006)
82:550–7. doi: 10.1097/01.tp.0000229473.95202.50
49. Demirkiran A, Hendrikx TK, Baan CC, van der Laan LJ. Impact
of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory
T cells: does in vitro evidence translate to the clinical setting?
Transplantation. (2008) 85:783–9. doi: 10.1097/TP.0b013e31
8166910b
50. Niu Q, Kraaijeveld R, Li Y, Mendoza Rojas A, Shi Y, Wang L,
et al. An overview of T follicular cells in transplantation: spotlight on
their clinical significance. Expert Rev Clin Immunol. (2019) 15:1249–
62. doi: 10.1080/1744666X.2020.1693262
51. Macedo C, Hadi K, Walters J, Elinoff B, Marrari M, Zeevi A, et al. Impact
of induction therapy on circulating t follicular helper cells and subsequent
donor-specific antibody formation after kidney transplant. Kidney Int Rep.
(2019) 4:455–69. doi: 10.1016/j.ekir.2018.11.020
52. Bouvy AP, Klepper M, Betjes MG, Weimar W, Hesselink
DA, Baan CC. Alemtuzumab as antirejection therapy: T cell
repopulation and cytokine responsiveness. Transplant Direct. (2016)
2:e83. doi: 10.1097/TXD.0000000000000595
53. Zwan M, Baan C, van Gelder T, Hesselink D. Review of the
clinical pharmacokinetics and pharmacodynamics of alemtuzumab
and its use in kidney transplantation. Clin Pharmacokinet. (2017)
57:191–207. doi: 10.1007/s40262-017-0573-x
54. Rosado-Sanchez I, Gonzalez-Magana A, Pozo-Balado MM, Herrero-
Fernandez I, Polaino MJ, Rodriguez-Mendez MM, et al. An in vitro system
of autologous lymphocytes culture that allows the study of homeostatic
proliferation mechanisms in human naive CD4 T-cells. Lab Invest. (2018)
98:500–11. doi: 10.1038/s41374-017-0006-3
55. Macedo C, Walters JT, Orkis EA, Isse K, Elinoff BD, Fedorek SP,
et al. Long-term effects of alemtuzumab on regulatory and memory T-
cell subsets in kidney transplantation. Transplantation. (2012) 93:813–
21. doi: 10.1097/TP.0b013e318247a717
56. LaMattina JC, Mezrich JD, Hofmann RM, Foley DP, D’Alessandro
AM, Sollinger HW, et al. Alemtuzumab as compared to
alternative contemporary induction regimens. Transpl Int. (2012)
25:518–26. doi: 10.1111/j.1432-2277.2012.01448.x
57. Noureldeen T, Albekioni Z, Machado L, Muddana N, Marcus RJ,
Hussain SM, et al. Alemtuzumab induction and antibody-mediated
rejection in kidney transplantation. Transplant Proc. (2014) 46:3405–
7. doi: 10.1016/j.transproceed.2014.08.037
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Niu, Mendoza Rojas, Dieterich, Roelen, Clahsen-van Groningen,
Wang, van Gelder, Hesselink, van Besouw and Baan. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 11 August 2020 | Volume 11 | Article 1972
